Navigation Links
Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
Date:2/20/2008

Patients Showing Excellent Tolerability at Higher Doses in Dose Escalation

EMERYVILLE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced that the higher doses of its innovative breast cancer drug candidate, BZL101 were well tolerated. As a result, the company will be extending the dose escalation portion of the study longer than previously communicated.

"We had expected to reach the maximum tolerated dose earlier, and then transition to the full Phase 2 component of the trial with that dose. Instead, we have seen very favorable tolerability data at the higher doses, and we are continuing to escalate the dose," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer. "As a result of this positive news, we will continue the dose escalation, so long as we continue to see favorable tolerability and safety, after which we will transition to the full Phase 2 study component."

Separately, Isaac Cohen, O.M.D., Bionovo's Chairman and CEO, stated, "We also completed further laboratory analyses on the mechanism of action and chemical characteristics of BZL101, which are striking and result in highly selective cancer cell killing. We expect to be presenting this data at key scientific conferences later this year, along with any available efficacy information."

About BZL101

BZL101 is an oral drug designed for the treatment of advanced breast cancer and pancreatic cancer with a novel mechanism of action. BZL101 targets cancer cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. In contrast, cancer cells depend largely on glycolysis (>85%) for ener
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Calif. , July 25, 2014  Depomed, Inc. ... will release second quarter fiscal year 2014 financial results ... Company will host a conference call beginning at 4:30 ... Participants can access the call by dialing 877-317-6789 ( ... conference call will also be available via a live ...
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... 2014  Acsis Inc., the market leader for ... has recently posted an article, "Future of ... future needs for companies, extended supply chain, and ... model no longer work today.  The article explains ... of mobile technology, machine to machine (M2M) connectivity, ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2Acsis Addresses Questions on the Modern Supply Chain 2
... There are some two dozen oncology therapies in Phase ... development. While only some of these therapies will make it ... a competitive marketplace where success revolves around planning as much ... in the oncology therapeutic area must constantly evaluate which factors ...
... April 20, 2012 A recent clinical trial conducted at ... drug used to treat Parkinson,s Disease greatly improves the quality ... such as tremors, slowness, stiffness and difficulty walking. ... hold the trial, which was led by Dr. C. Warren ...
Cached Medicine Technology:Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 2Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinson's Disease 3
(Date:7/28/2014)... FL (PRWEB) July 28, 2014 Termed ... prescription drug abuse causes more fatal overdoses than heroin ... a year. (1) Those who are particularly vulnerable to ... age and up), with many in this age group ... regarding this growing epidemic was reawakened in the White ...
(Date:7/28/2014)... has released a new blog post presenting ... Comparing life insurance quotes can help clients save up ... coverage is easier online by visiting insurance brokerage websites. ... them on a single web page. , By ... but they can also learn more about life insurance. ...
(Date:7/28/2014)... Thompson HealthDay Reporter FRIDAY, July ... 30-year policy that bans blood donations from gay and bisexual men, ... week in the Journal of the American Medical Association . ... man cannot donate blood in the United States -- a lifetime ... Food and Drug Administration adopted this policy at the dawn of ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July ... on contraception coverage -- as mandated under the Affordable Care ... allow companies to deny insurance coverage for any medical practice ... But other experts counter that such predictions are unlikely ... that Hobby Lobby Stores Inc. and Conestoga Wood Specialties Corp. ...
(Date:7/28/2014)... For those with dust allergies, home can be ... settle in mattresses, bedding, and upholstered furniture and elicit allergic ... microscopic insects that feed on the dead skin of pets ... a million dust mites fat and happy. When a speck ... decaying bodies and feces of dust mites can be seen.  ...
Breaking Medicine News(10 mins):Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 2Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 3Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 4Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 2Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 4Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 5Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 3
... is often on those already on drugs, some diagnoses ... (HealthDay News) -- A new study questions the commonly ... ) infections are always preceded by antibiotic use. , ... found that slightly more than half of senior citizens ...
... Wis., Oct. 10 More than 600 new Wisconsin,voters ... the,result of Aurora Health Care,s voter registration drives held ... system,s 13 hospitals across Eastern,Wisconsin. A total of 658 ... Aurora employees and volunteers, who were trained by the ...
... , ... Boston (Vocus) October 10, 2008 -- Several pediatric ... at the 2008 American Academy of Pediatrics National Conference and Exhibition, ... topics are listed below. , , Pediatrician Dana Best, ...
... Up with Legal and Medical Panel to Offer,Real-Life ... in,Knoxville, KNOXVILLE, Tenn., Oct. 10 In ... Careers and its founding partner,Roche have joined forces ... cancer advocate Holly Warlick, University of Tennessee,women,s basketball ...
... Honoring excellence in the implementation of electronic health records (EHRs), ... recipients of the 2008 Davies Awards in the Organizational, Ambulatory ... ... Chicago, IL (PRWEB) October 10, 2008 -- Honoring excellence ...
... Oct. 10 Accuray,Incorporated (Nasdaq: ARAY ), a ... it will report results for its first quarter fiscal,year ... 2008 after,the market closes., A conference call to ... p.m. EDT) and will be hosted by Euan S. ...
Cached Medicine News:Health News:Antibiotics May Not Cause Diarrheal Bacteria 2Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:Accuray Incorporated to Report First Quarter Fiscal Year 2009 Financial Results 2
Spectra Plus has been specifically designed as a compact, lightweight and portable indirect with big benefits for professionals on the move. It can be tucked away in its neat carrying case or hung ar...
Wampole Rubella-plus is an immunochromatographic assay for the qualitative detection of Rubella antibody (IgG) in human serum or plasma....
NOW Streptococcus pneumoniae is a rapid immunochromatographic assay for the detection of ,S. pneumoniae antigen in the urine of patients with pneumonia and in the cerebral spinal fluid of patients ...
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Medicine Products: